Medical device company focused on minimally invasive treatments for severe emphysema.
Pulmonx Corporation, a leading medical technology innovator, specializes in providing advanced minimally invasive devices tailored for the treatment of chronic obstructive pulmonary diseases (COPD). The cornerstone of its offerings includes the Zephyr Endobronchial Valve, designed to address hyperinflation in adults suffering from severe emphysema through bronchoscopic intervention. Additionally, Pulmonx offers the Chartis Pulmonary Assessment System, featuring a unique balloon catheter and console equipped with flow and pressure sensors. This system aids in evaluating collateral ventilation, crucial for determining the suitability of patients for Zephyr Valve treatment.
In expanding its comprehensive suite of solutions, Pulmonx introduced the StratX Lung Analysis Platform. This innovative cloud-based service utilizes quantitative computed tomography analysis to provide detailed insights into emphysema severity, fissure completeness, and lobar volume. Such precise data enables healthcare providers to identify optimal treatment targets within the lung lobes, enhancing the efficacy and customization of Zephyr Valve therapy.
Headquartered in Redwood City, California, Pulmonx Corporation operates on a global scale, serving COPD patients across diverse regions including the United States, Europe, the Middle East, Africa, and the Asia-Pacific. Founded in 1995 and initially known as Pulmonx, the company rebranded to Pulmonx Corporation in December 2013, reflecting its ongoing commitment to advancing pulmonary care through cutting-edge technology and patient-centric solutions.
With a legacy rooted in pioneering medical advancements, Pulmonx Corporation continues to drive innovation in the field of interventional pulmonology. Through strategic research, development, and collaboration, the company remains dedicated to improving the lives of patients worldwide by offering transformative therapies that address the complexities of chronic obstructive pulmonary diseases.